Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in Acutely Psychotic Subjects With Schizophrenia
NCT04072354Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of ulotaront in schizophrenia (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Sep 2019; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04072354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072354.